Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study.

ABSTRACT:

Background

Recent trends in use of tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonist (RA), versus other glucose-lowering medications (GLMs) and weight-lowering medications (WLMs) remain unexplored.

Objective

To describe trends in insurance claims for GLMs and WLMs after tirzepatide approval.

Design

Population-based cohort study.

Setting

Claims data from a large U.S. commercial database (January 2021 to December 2023).

Participants

Adults (aged ≥18 years) with type 2 diabetes (T2D) and without diabetes with dispensations for GLMs and WLMs. Any use was defined as medication dispensation regardless of prior use. Incident use was defined as dispensation without use in the preceding year.

SUBMITTER: Ostrominski JW 

PROVIDER: S-EPMC12718076 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature